We are very excited to have Dr. David Fajgenbaum as our student-selected keynote speaker on this momentous occasion of our 50th commencement ceremony. His impressive and

In September 2022, Fajgenbaum joined forces with longtime friend and fellow doctor Grant Mitchell, MD, and a group of experts at the University of North

Worldwide Clinical Trials (Worldwide), the industry’s leading global, full-service contract research organization (CRO), has partnered with Every Cure, a nonprofit organization that unlocks new, often

David Fajgenbaum is an immunologist and co-founder of Every Cure, a nonprofit organization whose mission is to unlock the full potential of approved medicines to

Fajgenbaum was having his last rites read to him, and his family braced for his death from Castleman disease, a rare inflammatory illness that impacts

A 50-year-old patient battling life-threatening Castleman disease was provided adalimumab as a treatment of last resort following its identification by AI-guided discovery. Every Cure and

About a decade ago, David Fajgenbaum thought his life was over. He was a young, bright physician hoping to work in oncology in remembrance of

David Fajgenbaum has become a “man on fire,” determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts

Two companies team up to combat rare diseases through drug repurposing, which was heavily informed by one doctor’s experience through unconventionally treating his Castleman disease

David Fajgenbaum, MD, was a college football player at Georgetown University in 2004 when his mother passed away from cancer. The loss inspired the athlete

As many as 7,000 rare diseases affect 300 million people globally. The vast majority are not well understood, and less than 5 percent have approved

Dr. David Fajgenbaum is not afraid to think outside the box and that is what saved his life. While in medical school, the former college

It was the night before April Fools’ Day, 2021, when Dr. David Fajgenbaum received the text: President Clinton read your book and would like to

The Philadelphia physician has the distinction of researching – and solving – his own rare disease. Learn more about this prolific advocate for rare disease

For biotechs, the JP Morgan Healthcare Conference is about dealmaking in many forms—securing financing, establishing development partnerships, courting mergers and acquisitions—by wooing would-be partners and

Medable has announced a collaboration with non-profit Every Cure for conducting global, remote clinical trials for drug repurposing candidates. Every Cure was officially launched, in

Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership

This week, an exciting interview from our archive airs on Oct. 8, 2022. A healthy young medical student, David Fajgenbaum, had been a student athlete

A new nonprofit backed by the Clinton Global Initiative aims to identify generic drugs that could help people with rare diseases. Every Cure is based

Approximately 75% of human diseases don’t have a single FDA-approved treatment. That fact nearly cost Dr. David Fajgenbaum his life, and at #CGI2022, he announced